



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/864,078
Applicants: : LaColla *et al.*
Filed : May 23, 2001
TC/A.U. : 1623
Examiner : Howard V. Owens, Jr.

Confirmation No. 9998

Docket No. : 06171.105022 (IDX 1007 US)
Customer No. : 20786

Mail Stop ISSUE FEE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

April 29, 2004

Terminal Disclaimer

Sir:

Assignees, Idenix Pharmaceuticals Inc. and the Universita Degli Studi Di Cagliari, the owners of the entire interest of U.S. Serial Nos. 09/864,078 and 09/863,816, through the undersigned agent of record, hereby disclaim the terminal part of any patent granted on U.S. Serial No. 09/864,078 that would extend beyond the expiration date of the full statutory term of U.S. Serial No. 09/863,816. Any patent granted on U.S. Serial No. 09/864,078 shall be enforceable only for and during such period that legal title to the patent that issues from U.S. Serial No. 09/864,078 shall be the same as legal title to the patent that issues from U.S. Serial No. 09/863,816 and will be binding upon the grantee, its successors or assigns.

Jean Pierre Sommadossi has assigned U.S. Serial Nos. 09/864,078 and 09/863,816 to Novirio Pharmaceuticals Limited, while Paola LaColla has assigned U.S. Serial Nos. 09/864,078 and 09/863,816 to the Universita Degli Studi Di Cagliari, whose addresses are of record, in Assignments recorded on February 26, 2001, at Reel 011545, Frame 0275 (for U.S. Serial Nos.

FEE ONLY

02/01/2005 DWARTINO 00000001 110980 09864078

01 FC:1814 110.00 DA